医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CANbridge Submits Investigational New Drug Application to Taiwan Food and Drug Administration for CAN-008 Phase I/II Trial in Glioblastoma

2016年04月07日 PM09:02
このエントリーをはてなブックマークに追加


 

BEIJING

CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that it has completed the Investigational New Drug (IND) application to the Taiwan Food and Drug Administration (TFDA) for a Phase I/II clinical study of CAN-008, plus temozolomide (TMZ), during and after radiation therapy, in patients with newly-diagnosed glioblastoma multiforme (GBM). The study will consist of an open-label, dose-escalation Phase I trial and a multi-center, double-blind, randomized, placebo-controlled Phase II trial. The Phase I trial will evaluate safety, tolerability, pharmacokinetics and preliminary efficacy. The Phase II trial will evaluate efficacy and safety. The combined Phase I/II trial will enroll a total of approximately 55 patients. CANbridge anticipates that the trial will commence in August 2016.

CAN-008 is a fully human fusion protein that inhibits the CD95 ligand, a member of the tumor necrosis factor (TNF) family. By blocking it, CAN-008 restores the immune system’s anti-tumor response and inhibits invasive tumor cell growth. In a European Phase II trial in patients with recurrent glioblastoma, conducted by the drug’s developer, privately-held Apogenix, patients with biomarkers for the CD95 ligand experienced the greatest benefits. In July 2015, CANbridge acquired an exclusive license to develop, manufacture and commercialize CAN-008 for GBM and other indications, in China, Hong Kong and Macau, which was recently expanded to include Taiwan.

Separately, CANbridge announced that it signed a partnership agreement with WuXi Biologics, a wholly-owned subsidiary of WuXi AppTec, for the manufacture of CAN-008 in China, in preparation for a glioblastoma IND submission to the China Food and Drug Administration (CFDA). The CFDA has recently initiated a Market Authorization Holder (MAH) pilot program to accelerate regulatory approval in China.

“This is CANbridge’s first IND submission and marks our imminent transition to a clinical-stage company,” said James Xue, CANbridge Chairman and CEO. “We are delighted to join forces with WuXi, which will manufacture CAN-008 for the Chinese market, where we plan to begin the pre-clinical work immediately, preparatory to an IND submission.”

“WuXi Biologics congratulates CANbridge for its rapid advancement to a clinical-stage company,” commented Chris Chen, PhD, Chief Executive Officer, WuXi Biologics. “We are thrilled to work with CANbridge to manufacture this important first-in-class biological drug candidate for the Chinese market, demonstrating the enabling power of our world-class proprietary biologics platform. By partnering with innovative companies, such as CANbridge, we will make life-saving biologics more affordable and available to the Chinese patients.”

About WuXi Biologics

WuXi Biologics, a wholly-owned subsidiary of WuXi AppTec, is a leading open-access technology capability and technology platform to enable anyone and any company to discover, develop and manufacture biologics. As a premier Contract Discovery, Development and Manufacturing Organization (CDMO), WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologics from concept to commercialization. Along with our WuXi AppTec affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics’ services, please visit: http://www.wuxibiologics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160407005405/en/

CONTACT

CANbridge Life Sciences
James Xue, +8610-8414-8018 or
781-995-0074
CEO
or
Planet Communications
Deanne
Eagle, 917-837-5866

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 国际纳米技术展览暨研讨会——2017纳米科技展将为您带来尖端技术与材料的最新资讯,令超智能社会触手可及
  • Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies
  • Bioventus选择MEDSERVICE作为DUROLANE®在俄罗斯的经销商
  • “nano tech 2017 国際ナノテクノロジー総合展・技術会議”開催、超スマート社会の実現に貢献する最先端技術・材料の最新情報を発信!
  • nano tech 2017, the International Nanotechnology Exhibition & Conference, Brings You the Latest Information on the Cutting Edge Technologies and Materials Making the Super Smart Society a Reality